Prospects and Challenges of Lung Cancer Vaccines.

Vaccines (Basel) · 2025 · PMC12390580 · PMID 40872921

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The combination significantly improved recurrence-free survival (RFS), reducing the risk of recurrence or death (HR = 0.561; 95% CI: 0.309–1.017; p = 0.0266), and also showed a trend toward improved distant metastasis-free survival (DMFS) [ 42 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.